Sequence information
Variant position: 306 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 393 The length of the canonical sequence.
Location on the sequence:
EENLRKKGEPHHELPPGSTK
R ALPNNTSSSPQPKKKPLDGE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human EENLRKKGEPH--HELPPGSTKR ALPNNTS-SSPQPK----KK----PLDGE
EENFHKKGEPC--PEPPPGSTKR ALPPSTS-SSPPQK----
Rhesus macaque EENFRKKGEPC--HQLPPGSTKR ALPNNTS-SSPQPK----
Mouse EENFRKKEVLC--PELPPGSAKR ALPTCTS-ASPPQK----
Rat EENFRKKEEHC--PELPPGSAKR ALPTSTS-SSPQQK----
Pig EENFLKKGQSC--PEPPPGSTKR ALPTSTS-SSPVQK----
Bovine EENLRKKGQSC--PEPPPRSTKR ALPTNTS-SSPQPK----
Rabbit EENFRKKGEPC--PELPPGSSKR ALPTTTTDSSPQTK----
Sheep EENFRKKGQSC--PEPPPGSTKR ALPSSTS-SSPQQK----
Cat EENFRKKGEPC--PEPPPGSTKR ALPPSTS-STPPQK----
Chicken EENFRKRGGAG-------GVAKR AMSPPTE-APEPPK----
Xenopus laevis EDNYTKKRGLK-----PSGKREL AHPPSSE--PPLPK----
Zebrafish ESNFKKDQETKTMAKTTTGTKRS LVKESSS-ATLRPEGSKK
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 393
Cellular tumor antigen p53
Region
1 – 320
Interaction with CCAR2
Region
100 – 370
Interaction with HIPK1
Region
282 – 325
Disordered
Region
300 – 393
Interaction with CARM1
Motif
305 – 321
Bipartite nuclear localization signal
Compositional bias
305 – 319
Polar residues
Modified residue
305 – 305
N6-acetyllysine
Modified residue
315 – 315
Phosphoserine; by AURKA, CDK1 and CDK2
Modified residue
321 – 321
N6-acetyllysine
Cross
291 – 291
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Cross
292 – 292
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Mutagenesis
319 – 319
K -> A. Loss of nuclear localization; when associated with A-320 and A-321.
Mutagenesis
320 – 320
K -> A. Loss of nuclear localization; when associated with A-319 and A-321.
Mutagenesis
321 – 321
K -> A. Loss of nuclear localization; when associated with A-319 and A-320.
Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.